Company intelligence / Profile preview
Zhixiang Jintai
Chongqing, China
- Ownership
- Public · 688443
- Development stage
- Other
01
Overview
The company’s lead asset, GR1803 injection, is a dual-specific antibody targeting BCMA and CD3, included in China’s breakthrough therapeutic variety list, with ongoing Phase I clinical data showing development progress. A separate program for suspected rabies exposure immunization is in the clinical trial application stage.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Dual-specific monoclonal antibodyMonoclonal antibodyAntibody
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Zhixiang Jintai.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhixiang Jintai.